FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

A correction has been published: N Engl J Med 2003;349(4):412.

Volume 348:2375-2376 June 12, 2003 Number 24 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article Related Article Related Article by Diehl, V. Related Article by Aleman, B. M.P. PubMed Citation

The greatest derangement of the mind is to believe in something because one wishes it to be so.

— René J. Dubos, 1876

The two articles on Hodgkin's disease in this issue of the Journal — one by Aleman et al. (pages 2396–2406) and one by Diehl et al. (pages 2386–2395) — provide an unusual opportunity to reflect on the evolution of the treatment of Hodgkin's disease and some of the mysterious ways in which competition among specialties affects the design of clinical trials.

In the 1960s, as part of a more global experiment on the curative potential of chemotherapy, . . . [Full Text of this Article]

Source Information

From the Yale Cancer Center, Yale University School of Medicine and Yale–New Haven Hospital, New Haven, Conn.

This article has been cited by other articles:

• Yahalom, J. (2006). Don't Throw Out the Baby With the Bathwater: On Optimizing Cure and Reducing Toxicity in Hodgkin's Lymphoma. JCO 24: 544-548 [Full Text]  
• Kaye, F. J., Harbour, J. W. (2004). For Whom the Bell Tolls: Susceptibility to Common Adult Cancers in Retinoblastoma Survivors. JNCI J Natl Cancer Inst 96: 342-343 [Full Text]  
• Diehl, V. (2004). Chemotherapy or Combined Modality Treatment: The Optimal Treatment for Hodgkin's Disease. JCO 22: 15-18 [Full Text]  
• Maignan, C. l., Desablens, B., Delwail, V., Dib, M., Berthou, C., Vigier, M., Ghandour, C., Atmani, S., Casassus, P., Maisonneuve, H., Mevel, A. L., Traulle, C., Bernard, M., Briere, J., Colonna, P., Andrieu, J.-M. (2004). Three cycles of adriamycin, bleomycin, vinblastine, and dacarbazine (ABVD) or epirubicin, bleomycin, vinblastine, and methotrexate (EBVM) plus extended field radiation therapy in early and intermediate Hodgkin disease: 10-year results of a randomized trial. Blood 103: 58-66 [Abstract] [Full Text]